Compound Radar

Alvotech (ALVO) Stock Analysis

Price $4.75
Market cap $1.69B
Next earnings Nov 11, 2026
Entry status Wait

Last updated Oct 27, 2026

Health Check

Last analyzed Oct 23, 2026

45
45/100 Speculative
  • Financial Health 30
  • Profitability 70
  • Business Quality 65
  • Balance Sheet 30
  • Cash Flow 25

Why this rating?

Health 45/100 — Speculative

Strongest Profitability 70/100
Softest Cash Flow 25/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Alvotech (ALVO) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Alvotech 45/100 (Speculative) due to solid business quality, elevated leverage, and fair valuation.

Investment profile

  • Quality Moderate
  • Growth Soft
  • Balance Sheet Stretched
  • Valuation Fair

Financial highlights

Valuation

  • Forward P/E 20.64
  • EV/Revenue 5.98

Profitability

  • Revenue Growth -38.9%
  • Gross Margin 60.7%
  • Operating Margin -11.1%
  • Net Margin -36.3%

Financial strength

  • Cash $142.75M
  • Debt $1.45B
  • Net Cash $-1.31B
  • Free Cash Flow $-146.33M
  • Current Ratio 1.65

Similar companies

Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Drug Manufacturers - Specialty & Generic →

FAQ

How Compound Radar scores and tracks Alvotech (ALVO).

View Methodology & FAQ →